Living Cell Technologies Limited (LCT) is an Australia-based biotechnology company. The Company is focused on discovering and developing treatments for conditions, such as diabetes and Parkinson’s disease. It operates in both Australia and New Zealand, being the research and development and product development into living cell technologies. The Company’s product candidate includes NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. Choroid plexus cells are naturally occurring support cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT’s technology IMMUPEL to protect them from attack by the immune system. The Company has completed two clinical trials of NTCELL in Parkinson’s disease.